Introduction {#sec1}
============

Waddington's "epigenetic landscape" model suggests that the process of cellular differentiation is essentially irreversible ([@bib57]). However, it is now clear that differentiated cells can be reprogrammed into a pluripotent state ([@bib26; @bib51]) or into an alternative differentiated state ([@bib56]). Therefore, the differentiated state of cells is not set in stone; cells can dedifferentiate or transdifferentiate. However, the more differentiated a cell is, the more difficult it is to reprogram (for review, see [@bib42]), suggesting that there are active mechanisms in place to maintain cells in a differentiated state. Although there are now many studies defining the transcription factors that enable reprogramming, less is known about the mechanisms that act to prevent cells from dedifferentiating. Identification of these mechanisms will be key for fully understanding reprogramming and for developing safe methods for dedifferentiating cells in vivo for therapeutic purposes without inducing cancer ([@bib55; @bib45]).

The *Drosophila* CNS is an attractive model for studying differentiation of neural stem cells and their progeny as well as investigating how misregulation of self-renewal and differentiation can lead to tumorigenesis ([@bib59; @bib11; @bib17; @bib20; @bib38]). The majority of neural stem cells in the *Drosophila* brain and ventral nerve cord (type I neuroblasts) undergo multiple asymmetric divisions whereby they self-renew while producing daughter cells (GMCs or ganglion mother cells) that divide only once to give two postmitotic neurons or glial cells. At each division, cell-fate determinants are segregated from the neural stem cell to the GMC. These include Prospero ([@bib18; @bib54; @bib37]), Brat ([@bib3; @bib5; @bib32]), and Numb ([@bib44]), all of which act as tumor suppressors in the nervous system ([@bib3; @bib5; @bib14; @bib31; @bib32; @bib58; @bib7]). Therefore, disrupting the neurogenic differentiation pathway can lead to tumorigenesis.

We showed previously that the atypical homeodomain transcription factor, Prospero, controls the choice between stem cell self-renewal and differentiation. Prospero represses genes required for self-renewal, such as neural stem cell genes and cell-cycle genes but also is required to activate genes for neuronal and glial differentiation ([@bib14]). In *prospero* mutants, GMCs fail to differentiate and revert to a stem cell-like fate. They continue to divide, express neural stem cell markers, and form brain tumors ([@bib10; @bib3; @bib5; @bib14; @bib32]).

Prospero's ability both to repress and to activate transcription suggested that cofactors and/or chromatin remodeling factors might modulate Prospero's activity. Prospero is known to function with a histone deacetylase (HDAC), Rpd3, to control dendritic targeting in postmitotic neurons ([@bib52]). The vertebrate homolog of Prospero, Prox1, also interacts with an HDAC (HDAC3; [@bib47]) as well as with nuclear hormone receptors ([@bib35; @bib50; @bib33; @bib12]). To date, no factors have been identified that act with Prospero in the switch from self-renewal to differentiation.

Here, we show that the BTB-Zn finger transcription factor, Lola ([@bib46; @bib23]), binds to a large number of Prospero's targets, including genes involved both in stem cell self-renewal and differentiation. Furthermore, like Prospero, Lola is a tumor suppressor protein. Intriguingly, however, the tumor cell of origin in *lola* mutants differs from that in *prospero* mutants. Unlike *prospero* mutants where the first daughter of the neural stem cell, the GMC, reverts to a stem cell-like state, in *lola* mutants newly born neurons dedifferentiate, express stem cell markers, and proliferate, resulting in brain tumors. We conclude that, whereas Prospero acts to block self-renewal and initiate neuronal differentiation, Lola is required to maintain the differentiated state.

Results {#sec2}
=======

Identification of a Prospero Cofactor {#sec2.1}
-------------------------------------

Given that Prospero has the ability both to repress and activate gene expression ([@bib14]), we reasoned that Prospero is likely to act with proteins that are able to modulate its activity. To identify the binding sites for potential cofactors, we analyzed the DNA sequences near Prospero binding sites using the motif discovery tool MICRA ([@bib48]). MICRA identifies enriched sequences at Prospero binding sites by extracting and filtering for conserved sequences and calculating the relative frequency of each 6--10-mer as compared to the background frequency throughout the genome. The most enriched 6-mer at Prospero binding sites, to which Prospero itself does not bind ([@bib16; @bib61]), is the conserved palindromic sequence, CGATCG (166% enriched). Furthermore, alignment of the most enriched 8-mer generates a position weight matrix (PWM) containing a core CGATCG sequence ([Figure 1](#fig1){ref-type="fig"}A). Members of the GATA zinc finger transcription factor family ([@bib8]) bind a similar sequence (GATDV, GATYDD).

To identify proteins that recognize this motif, we performed a yeast one-hybrid screen using six copies of the motif as bait and an embryonic cDNA library as prey. We isolated a specific isoform of the BTB-zinc finger transcription factor Lola, Lola-N. The *lola* locus generates 25 different splice isoforms encoding 20 proteins that share the same N-terminal BTB domain but different C termini, which can encode one of 17 different zinc fingers, or lack zinc fingers entirely ([@bib24; @bib41]) ([Figure 1](#fig1){ref-type="fig"}B). Each of these zinc fingers can potentially bind a unique DNA sequence.

Lola-N Is Expressed in Neurons {#sec2.2}
------------------------------

If Lola acts with Prospero, then we expected that the two proteins would colocalize at some point in development. To determine the expression pattern of Lola-N, we generated an antibody against its unique C terminus. Lola-N is expressed in embryos from stage 11 onward in the differentiating layer of the ventral nerve cord (VNC) but not in neuroblasts ([Figures 2](#fig2){ref-type="fig"}A and 2B). Lola-N is expressed in all neurons, colocalizing with Elav, but is undetectable in glial cells ([Figures 2](#fig2){ref-type="fig"}C and 2D). Lola-N is also expressed in neurons of the larval and adult brain ([Figure 2](#fig2){ref-type="fig"}G and [Figures S1](#app3){ref-type="sec"}A--S1G available online).

During neural stem cell self-renewal, Prospero is segregated from the neuroblast to the GMC. After the GMC has divided, Prospero is present only transiently in the resultant neurons ([@bib49]). Lola-N expression is induced as Prospero levels decrease, resulting in a brief period of colocalization ([Figure 2](#fig2){ref-type="fig"}E) immediately before, and just after, GMC division, as determined by phosphohistone H3 (PH3) labeling (arrowheads in [Figure 2](#fig2){ref-type="fig"}F).

Lola-N is expressed in a similar manner in the larval CNS ([Figures 2](#fig2){ref-type="fig"}G and [S1](#app3){ref-type="sec"}A--S1C), except that it overlaps more extensively with Prospero in the central brain ([Figure S1](#app3){ref-type="sec"}C) where Prospero is present in at least a subset of postmitotic neurons ([@bib3; @bib52]). Therefore, Lola-N is expressed at an appropriate time and place to act with Prospero or to modulate its activity.

Lola-N Represses Neuroblast Genes and Cell-Cycle Regulators {#sec2.3}
-----------------------------------------------------------

To assess whether Lola binds to the same genes as Prospero, we identified the embryonic binding sites of Lola-N throughout the genome using DamID. Lola-N binds to 1,369 genes (false discovery rate \[FDR\] \< 0.1%) that show a highly significant overlap (p \< 6 × 10^−71^) with the 836 genes (FDR \< 0.1%) bound by Prospero. Two hundred fifty-nine genes are bound by both Prospero and Lola-N (31% of Prospero's targets; [Figure 3](#fig3){ref-type="fig"}A; [Experimental Procedures](#sec4){ref-type="sec"}). This overlap is specific to Prospero and Lola-N because only five of the 259 genes (2%) are bound by an unrelated neural transcription factor (P. Wu and A.H.B., unpublished data).

Analysis of the Lola-N binding peaks reveals that the most enriched 6-mer (CGATCG, 253% enriched) is identical to the motif identified by MICRA analysis of the sequences associated with Prospero binding peaks, as described above. The core CGATCG sequence is again integral to a PWM generated from enriched 8-mer ([Figure 3](#fig3){ref-type="fig"}B) and provides independent support for the yeast one-hybrid result.

Lola-N binds both neural stem cell genes and differentiation genes ([Figure 3](#fig3){ref-type="fig"}A). Both Lola-N and Prospero bind key neuroblast genes and cell-cycle regulators ([Figures 3](#fig3){ref-type="fig"}C, 3E, and 3G), including *brain tumor* (*brat*), *deadpan* (*Hes* family related), *dacapo* (*p27cip/kip*), and *string* (*cdc25*). They also bind to many Notch family genes, suggesting that Prospero and Lola-N coordinately regulate this pathway. Interestingly a second isoform of Lola, Lola-T, has been shown to antagonize Notch during specification of cell fate in the developing *Drosophila* eye ([@bib62]).

To determine how Lola-N regulates its target genes, we expressed Lola-N ectopically in stripes in the developing embryo. In cells expressing Lola-N, driven by *engrailed-GAL4*, transcription of the cell-cycle genes *CyclinE* and *string* (*cdc25*) is repressed ([Figures 3](#fig3){ref-type="fig"}F and [2](#fig2){ref-type="fig"}H). Transcription of the genes encoding the neuroblast transcription factors, *deadpan* and *asense*, is also repressed by Lola-N ([Figures 3](#fig3){ref-type="fig"}D, [S2](#app3){ref-type="sec"}A, and S2B). Therefore, like Prospero, Lola-N is able to directly bind and repress neural stem cell genes. This is intriguing as Lola-N is first expressed just prior to the GMC's terminal division ([Figure 2](#fig2){ref-type="fig"}F), at which point Prospero would already have repressed neural stem cell genes. This suggests that Lola-N's role might be in maintaining, rather than in initiating, repression of these genes.

Loss of *lola* Causes Tumors {#sec2.4}
----------------------------

If Lola-N is required to maintain the differentiated state, then the loss of Lola might result in tumor formation, similar to what has been observed in *prospero* mutants. Prospero is required to block self-renewal and induce differentiation. As a result, the loss of *prospero* leads to tumor formation in the developing *Drosophila* nervous system. In *prospero*, mutant GMCs, which would normally divide terminally to generate postmitotic neurons, instead undergo self-renewing divisions ([@bib14; @bib32]).

We generated *lola*^*E76*^ mutant clones during larval stages using the MARCM system ([@bib30]). *lola*^*E76*^ is a protein null mutation, removing all isoforms of *lola* ([@bib24]). *lola*^*E76*^ mutant clones proliferate extensively and give rise to tumors in the adult brain ([Figures 4](#fig4){ref-type="fig"}B and 4C). The mutant cells express the neuroblast transcription factor, Deadpan ([Figure 4](#fig4){ref-type="fig"}B), and divide actively as indicated by labeling with phosphohistone H3 ([Figure 4](#fig4){ref-type="fig"}C). We observed a similar phenotype with an independent *lola* mutant allele, *lola*^*5D2*^ ([@bib23]) (data not shown). *lola*^*E76*^ mutant clones form tumors in the optic lobe region of the adult brain (n \> 30) but not in the central brain, in contrast to *prospero* mutant clones, which can generate tumors in both regions ([@bib3; @bib5; @bib32]) ([Figure 4](#fig4){ref-type="fig"}A). Interestingly, Prospero expression persists in the central brain but not in the optic lobe. It is conceivable that Prospero is able to maintain the repression of neural stem cell genes in the central brain in the absence of Lola. In support of this hypothesis, ectopic expression of Prospero is able to rescue the *lola* tumor phenotype ([Figures 4](#fig4){ref-type="fig"}E and 4F).

A previous study described the formation of tumors in the larval central brain when *lola* was knocked down using RNAi ([@bib39]). However, RNAi is prone to off-target effects. We have never observed tumor formation in the central brain in two different *lola* null mutants (*lola*^*E76*^ and *lola*^*5D2*^), nor after expression of a small hairpin RNA (shRNA) ([@bib40]) targeting *lola* ([Figure S6](#app3){ref-type="sec"}A). The same study reported a neuroblast underproliferation phenotype after knockdown of *lola-N* in neuroblasts. As *lola-N* is not expressed in neuroblasts, this is likely also to be due to off-targets.

To test whether the loss of Lola-N is critical for tumor formation, we expressed *lola-N* in *lola*^*E76*^ mutant clones. Expression of *UAS-lola-N* was driven by *elav-GAL4* to most closely replicate wild-type *lola-N* expression. *lola*^*E76*^ clones expressing *lola-N* never form tumors (nine of nine brains; [Figure 4](#fig4){ref-type="fig"}D). In contrast, neither Lola-F nor Lola-H is able to inhibit tumor formation (C. Howard, T.D.S., and A.H.B., unpublished data). Interestingly, ectopic expression of Lola-N is also able to suppress the *prospero* mutant phenotype in embryos, preventing Deadpan expression and cell proliferation ([Figure S3](#app3){ref-type="sec"}). Therefore, like Prospero, Lola-N acts as a tumor suppressor.

Neurons Lacking *lola* Dedifferentiate {#sec2.5}
--------------------------------------

Lola-N is expressed in postmitotic neurons, implying that there is active repression of stem cell genes in postmitotic neurons and raising the possibility that *lola* mutant tumors arise through the dedifferentiation of neurons. To test this hypothesis, we investigated the timing of tumor formation and the cell type of origin in *lola* mutants.

In *prospero* mutants, tumors arise from GMCs that revert to a stem cell-like fate, expressing neuroblast genes such as Deadpan ([@bib14; @bib32]). In wild-type embryos, Deadpan is expressed in neuroblasts, which lie ventrally (red cells in [Figure 5](#fig5){ref-type="fig"}A). When Prospero moves into the nucleus of GMCs, Deadpan expression is rapidly repressed (green cells in [Figure 5](#fig5){ref-type="fig"}A). In *lola* mutant embryos, Deadpan is switched off normally in GMCs ([Figure 5](#fig5){ref-type="fig"}B) but is then ectopically expressed in the dorsal, differentiated layer of the VNC, where neurons are positioned (arrowheads in [Figure 5](#fig5){ref-type="fig"}B). These cells are not GMCs or newly born neurons as they do not express Prospero ([Figure 5](#fig5){ref-type="fig"}B). To confirm that these cells are neurons, we costained with Fasciclin II, which is expressed in neurons but not neuroblasts ([@bib29]). In wild-type embryos, Deadpan (neuroblasts) and Fasciclin II (neurons) are never coexpressed ([Figure 5](#fig5){ref-type="fig"}C); however, *lola* mutant neurons express both Fasciclin II and Deadpan, both in the embryo ([Figure 5](#fig5){ref-type="fig"}D) and in the larval optic lobe ([Figure 5](#fig5){ref-type="fig"}E). We observed Deadpan coexpressed with two further neuronal markers, Cut and Elav (arrowheads in [Figures 5](#fig5){ref-type="fig"}F and [S4](#app3){ref-type="sec"}). Therefore, Deadpan is properly repressed in GMCs but is then derepressed in neurons.

Next, we followed the progression over time of *lola*^*E76*^ mutant clones in the larval optic lobe ([Figures 6](#fig6){ref-type="fig"}A--6C and [S5](#app3){ref-type="sec"}C). The timing and position of the Deadpan-expressing cells provided further confirmation that neurons, rather than GMCs, are the tumor-initiating cells. Initially, we observed only neurons in *lola* mutant clones in the medulla cortex (∼48 hr; only 1% of *lola* mutant medulla cortex cells show Deadpan expression). By ∼72 hr, Deadpan began to be expressed in regions of the medulla cortex where only postmitotic neurons normally reside (5% of *lola* mutant cells) ([Figure 6](#fig6){ref-type="fig"}B). By ∼96 hr, multiple Deadpan-positive cells were found in mutant clones (17%) in the differentiated outer medulla cortex ([Figure 6](#fig6){ref-type="fig"}C). We observed ectopic expression of two further neuroblast genes, Asense and Worniu, in the medulla cortex ([Figures 6](#fig6){ref-type="fig"}D and [S5](#app3){ref-type="sec"}A). The expression of neuroblast genes coincides with cells entering the cell cycle and actively dividing ([Figure 6](#fig6){ref-type="fig"}E). We observe PH3-positive cells in deep layers of the medulla cortex, indicating that the *lola* mutant cells are actively proliferating in a region of the brain where there is normally little or no cell division ([Figure 6](#fig6){ref-type="fig"}E, compare *lola* mutant cells to surrounding wild-type neurons). Consistent with us never observing tumors in the adult central brain, ectopic Deadpan is not present in *lola* mutant clones in the larval central brain ([Figure S5](#app3){ref-type="sec"}B).

Knockdown of *lola* in neurons (*elav-GAL4*-driven expression of a shRNA; [@bib40]) results in dedifferentiation of neurons in the optic lobe and the formation of tumors in the adult brain ([Figures 7](#fig7){ref-type="fig"}B and [Figure S6](#app3){ref-type="sec"}A). *elav-GAL4* was reported to be expressed weakly in neuroblasts ([@bib4]). To exclude the possibility that knockdown of *lola* in neuroblasts contributes to the tumor phenotype, we drove *lola shRNAi* with *GAL4*^*C855a*^ ([@bib19]). *GAL4*^*C855a*^ is expressed in the neuroepithelium, in optic lobe neuroblasts and in GMCs ([Figures S6](#app3){ref-type="sec"}C--S6E). We never see tumors when *lola* is knocked down in these cell types. Therefore, tumors arise only when *lola* is knocked down in neurons. In addition, there is little or no expression of *elav-GAL4* in neuroblasts in our clonal experiments (see [Figure 7](#fig7){ref-type="fig"}B). We conclude that *lola* mutant neurons dedifferentiate, express stem cell genes, and proliferate giving rise to brain tumors in the adult.

Discussion {#sec3}
==========

Our results reveal the temporal progression toward neuronal differentiation. First, Prospero enters the nucleus of the newly born GMC and initiates the repression of neural stem cell genes. Next, Lola-N is expressed and maintains transcriptional repression in postmitotic neurons, acting as a differentiation "lock" ([Figures 7](#fig7){ref-type="fig"}C and 7D). Transcription factors that act as differentiation locks have been identified in other cell types (e.g., Pax5 in B cells; [@bib15]), but not in neurons. Mutations like *midlife crisis* ([@bib9]), which lead to the transient derepression of neuroblast genes, are insufficient to cause neurons to dedifferentiate and revert to a proliferating stem-cell-like state, nor do they result in tumorigenesis.

We show that Lola-N is a potent repressor of neural stem cell genes. Studies on vertebrate BTB-ZFs have revealed that they act predominantly as transcriptional repressors (for review, see [@bib28]), although some, such as Miz-1, can act as both repressors and activators ([@bib1]). For several BTB-ZFs, transcriptional repression is elicited through HDACs, which deacetylate histones and promote a "closed" chromatin state ([@bib28]). Therefore, as found for vertebrate BTB-ZFs, Lola-N may act through HDACs to achieve this repression.

The vertebrate proteins most similar to Lola are Zfp131, Miz-1, and Leukemia-Related Factor (LRF). Of these, Zfp131 is expressed predominantly in the developing nervous system, the adult brain, and the testes ([@bib53]), a similar expression pattern to that described for *lola-N* in flies (FlyAtlas; [@bib13]). Miz-1 is also expressed in neurons in the developing and adult mouse brain (Allen Brain Atlas; [@bib34]) and has a potent growth arrest function ([@bib43]). Zfp131 and Miz-1 may be functionally analogous to Lola-N, with respect to promoting or maintaining neuronal differentiation.

That Lola-N represses cell-cycle genes in postmitotic neurons seems surprising at first; however, there is a growing body of evidence to suggest that neurons must continuously keep the cell cycle in check (for review, see [@bib27]). Inhibition of Retinoblastoma (Rb) in Purkinje neurons forces neurons to reenter the cell cycle and replicate their DNA, but M phase is not initiated and the neurons die ([@bib21]). Similarly, knockdown of Cdh1, which is required to prevent the accumulation of cyclin B1 in neurons, causes neurons to enter S phase and leads to apoptosis ([@bib2]). Therefore, repression of cell-cycle genes is imperative as aberrant cell-cycle activity in neurons can lead to neurodegeneration or cancer.

Growing evidence suggests that there is plasticity between stem cells and their more differentiated progeny ([@bib25]) and that some more differentiated cells, for example, intestinal secretory progenitors ([@bib55]) and intestinal epithelial cells ([@bib45]), can initiate tumors. In *lola* mutants, the tumor cells of origin are postmitotic neurons rather than GMCs ([Figure 7](#fig7){ref-type="fig"}E). In contrast to *prospero* mutants, GMCs differentiate normally in *lola* mutants, and Deadpan is repressed. Newly born neurons, however, dedifferentiate, reexpress Deadpan, and undergo cell division resulting in adult brain tumors.

Interestingly, the loss of *lola* does not cause tumor formation in the central brain, where Prospero expression persists in neurons. The diagrams in [Figures 7](#fig7){ref-type="fig"}C and 7D depict the expression of Deadpan, Prospero, and Lola-N, during neurogenesis in *wild-type* and *lola* mutants. In *lola* mutant embryos and larval optic lobe clones, Prospero is switched off in neurons and Deadpan is reexpressed ([Figure 7](#fig7){ref-type="fig"}C). However, in the larval central brain, Prospero remains on in neurons ([Figure 7](#fig7){ref-type="fig"}D). We have shown that Prospero expression can rescue the *lola* tumor phenotype ([Figures 4](#fig4){ref-type="fig"}E and 4F); therefore, the persistence of Prospero in central brain neurons may explain why Deadpan is not reexpressed and why tumors are not observed in the adult central brain.

We hypothesize that Lola maintains the repression of neural stem cell genes until they transition to a more permanent "off state." BTB-zinc finger proteins are known to recruit HDACs, and this may be the mechanism by which target genes are more permanently locked down. In support of this hypothesis, we find that knockdown of *lola* in adult flies is no longer sufficient to cause neuronal dedifferentiation ([Figure S6](#app3){ref-type="sec"}B).

A long-term goal of regenerative medicine and stem cell research is to convert cells in vivo to specific fates to allow for the repair of damaged or diseased tissues. The ability to induce neurons to dedifferentiate, followed by directed differentiation to neurons of choice, would be an ideal method of repair. Mature neurons have been shown to dedifferentiate when p53 and NF1 are knocked down simultaneously. However, this leads to genome instability resulting in gliomas ([@bib22]). Our data suggest that a single factor can maintain the global repression of both cell-cycle genes and neural stem cell genes in postmitotic neurons. Factors such as Lola would be excellent targets for realizing the goal of controlled dedifferentiation of neurons in vivo.

Experimental Procedures {#sec4}
=======================

Fly Lines {#sec4.1}
---------

*UAS-lola-N*, *UAS-lola-H*, *UAS-lola-F*, and *UAS-Dam-lola-N* flies were generated by PCR amplifying the full coding sequences from an embryonic cDNA library and cloning it into pUASTattB ([@bib6]) and pUAST-NDam ([@bib14]), respectively (for primer sequences, see [Supplemental Experimental Procedures](#app3){ref-type="sec"}). Transgenic flies were generated as previously described ([@bib14]). *UAS-lola-shRNAi* (based on the approach described by [@bib40]) was generated using the method available on the TRiP website (<http://www.flyrnai.org/supplement/2ndGenProtocol.pdf>) using the passenger strand sequence CACGACAGATCTCAGGATGAA and the pWALIUM20 vector. MARCM clones were generated using the following driver lines: *elav-GAL4*, *UAS-mCD8-GFP*, *hsFLP*; *FRT42D*, *tub-Gal80/CyO* and *tub-GAL4*, *UAS-nuGFP*, *hsFLP*; *FRT42D*, *tub-Gal80/CyO*, and the following FRT lines: *lola*^*E76*^, *FRT42D/CyO*, *lola*^*5D2*^, *FRT42D/CyO*, *lola*^*E76*^, *FRT42D/CyO*; *UAS-lola-N/TMBb*, and *FRT42D*; *UAS-lola-shRNAi*. *lola*^*E76*^ is a protein null mutation, removing all isoforms of *lola* ([@bib24]). *lola*^*5D2*^ (P-element insertion at the transcriptional start site) is a strong hypomorph for *lola* ([@bib23]). *w*^*1118*^ were used as *wild-type* flies for immunohistochemistry experiments.

Yeast One-Hybrid {#sec4.2}
----------------

The yeast one-hybrid assay was performed using the Matchmaker Yeast One-Hybrid kit (Clontech) and protocol. To make the DNA bait construct, we first modified the Clontech bait vector pHis2.1 to make it compatible with our cDNA library by replacing the Trp selection gene with the Leu selection gene to give pHis2.2. An oligo with six copies of the bait site interspersed with random 5-mer ([Supplemental Experimental Procedures](#app3){ref-type="sec"}) was annealed to its reverse complement and cloned into pHis2.2 using MluI and SpeI. This was transformed into Y187 yeast. One hundred micrograms of a 4--17 hr embryonic cDNA library (with cDNAs fused to an activator domain) was transformed into yeast carrying the bait construct and plated onto −His/−Leu/−Trp selective media containing 50 mM 3-AT. Positive colonies were picked, suspended in 0.2% SDS, heated at 95°C for 5 min, and centrifuged, and the supernatant was purified using a QIAGEN PCR purification kit. For sequencing, the cDNA inserts were PCR amplified (for primer sequences, see [Supplemental Experimental Procedures](#app3){ref-type="sec"}) and sequenced using the forward primer.

Immunohistochemistry {#sec4.3}
--------------------

Larval and adult CNS were dissected in PBS and then fixed for 15--20 min in PBS containing 4% formaldehyde (ultra pure), 0.5 mM EGTA, and 5 mM MgCl~2~. Wash solution was PBS with 0.3% Triton X-100. The anti-Lola-N antibody was generated by synthesis of the peptides GVELDSIDDTMTEV and GSPLSWTYDAVKIC (corresponding to the unique C-terminal region) and injection into rabbits (Moravian Biotechnology). Serum was purified using the GVELDSIDDTMTEV peptide and used at a concentration of 1:10. Other primary antibodies used were chicken anti-GFP (1 in 2,000) (ab13970, Abcam), mouse anti-Discs Large (c) (1 in 70) (4F3, Developmental Studies Hybridoma Bank \[DSHB\]), rat anti-Elav (c) (1 in 70) (7E8A10, DSHB), mouse anti-Fas II (c) (1 in 20) (1D4, DSHB), guinea pig anti-Deadpan (1 in 500) (J.B. Skeath), mouse anti-Repo (c) (1 in 70) (8D12, DSHB), rabbit anti-PH3 (1 in 100) (06-570, Upstate), rat anti-PH3 (1 in 150) (ab10543, Abcam), mouse anti-Prospero (c) (1 in 70) (MR1A, DSHB), mouse anti-Cut (c) (1 in 30) (2B10, DSHB), rat anti-Worniu (0.8 in 1) (C.Q. Doe), rabbit anti-Asense (1 in 1000) (Y. N. Jan). Appropriate combinations of Alexa-coupled secondary antibodies (Invitrogen) were subsequently applied. Phalloidin-546 (Invitrogen) was used for actin staining (1 in 100). Samples were analyzed with a Leica SP2, Leica SP5, or Zeiss LSM510 confocal microscope. Adobe Photoshop and Illustrator were used to generate figures.

DamID {#sec4.4}
-----

Preparation of Dam-methylated DNA from stage 10--11 embryos was performed as previously described ([@bib14]). The Dam-only and Dam-Lola-N samples were labeled and hybridized together on a whole genome 2.1 million feature tiling array, with 50- to 75-mer oligonucleotides spaced at approximately 55 bp intervals (Nimblegen systems). Arrays were scanned and intensities extracted (Nimblegen Systems). Three biological replicates (with one dye-swap) were performed. Log2 ratios of each oligo were median normalized.

DamID Analysis {#sec4.5}
--------------

A peak finding algorithm with FDR analysis was used to identify significant binding sites ([@bib60]) (PERL script available on request). All peaks spanning four or more consecutive probes (greater than ∼900 bp for low-density arrays and greater than ∼400 bp for high-density arrays) over a 2-fold ratio change were assigned a FDR value.

Motif Analysis {#sec4.6}
--------------

A perl program was used to identify peak structures within the DamID data (script available on request), and the top 1,000 peaks (based on peak height) were analyzed using the MICRA program ([@bib48]). Lola-N data were first converted to release four coordinates before running MICRA. To generate a PWM from enriched 8-mer, the top 50 enriched 8-mer were analyzed by MEME-ChIP ([@bib36]), with their abundance represented in the input fasta file.

In Situ Hybridizations {#sec4.7}
----------------------

In situ hybridization was performed as previously described ([@bib14]). For primer sequences used to generate in situ probes, see the [Supplemental Experimental Procedures](#app3){ref-type="sec"}.

Accession Numbers {#app1}
=================

The DamID-chip data have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus under accession number [GSE53447](ncbi-geo:GSE53447){#intref0015}.

Supplemental Information {#app3}
========================

Document S1. Supplemental Experimental Procedures and Figures S1--S6
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![Experimental Design for Identifying a Prospero Cofactor\
(A) An enriched motif was identified at regions in the genome bound by Prospero. In the Prospero DamID binding data example, the vertical bar represents the log2 ration between the Dam-Prospero signal and the Dam-only signal. This motif identified was used in a yeast one-hybrid screen to identify Lola splice isoform N as a protein that can bind to this DNA sequence.\
(B) Structure of the *lola* locus. *lola* generates 25 different splice isoforms that all share a N-terminal BTB domain but possess one of 17 differing C-terminal zinc finger domains. The isoform identified in the yeast one-hybrid screen is highlighted (Lola-N).](gr1){#fig1}

![Lola-N Is Expressed in Neurons in the Developing Nervous System\
(A and B) Lola-N protein is absent from neuroblasts and present in the differentiating, dorsal region of the VNC (lateral view, stage 14 embryo). Arrowhead highlights a neuroblast.\
(C) Colocalization of Lola-N and the neuronal marker Elav (ventral view, stage 16/17 embryo).\
(D) Mutually exclusive expression pattern of Lola-N and the glial marker Repo (ventral view, stage 16/17 embryo).\
(E) Lola-N and Prospero briefly overlap in differentiating cells of the VNC (lateral view, stage 14 embryo). Arrowheads identify example cells that express both Lola-N and Prospero.\
(F) Colocalization of low levels of Lola-N with PH3 in the VNC (ventral view, stage 13 embryo). Arrowheads show dividing GMC cells.\
(G) Lola-N and Prospero expression in third instar larval brains.\
Scale bars represent 20 μM. See also [Figure S1](#app3){ref-type="sec"}.](gr2){#fig2}

![Transcriptional Targets of Lola-N\
(A) Comparison of Lola-N and Prospero target genes in the developing embryo.\
(B) Identification of the most enriched DNA motif at sites of Lola-N binding. In the Lola-N DamID binding data example, the vertical bar represents the log2 ratio between the Dam-Prospero signal and the Dam-only signal.\
(C, E, and G) Lola-N and Prospero binding at the *dpn*, *CycE*, and *string* loci. The vertical bars represent the log2 ration between the Dam-fusion signal and the Dam-only signal. Red bars indicate regions identified as being significantly bound.\
(D, F, and H) Lola-N is sufficient to repress the expression of *dpn*, *CycE*, and *string* mRNA in the developing embryo.\
See also [Figure S2](#app3){ref-type="sec"}.](gr3){#fig3}

![Loss of Lola Causes Brain Tumors\
(A) *prospero* mutant clones result in tumors in the adult brain, in both the central brain and optic lobe regions.\
(B and C) *lola*^*E76*^ mutant clones cause tumors in the optic lobe regions of the adult brain. The tumors express the neuroblast marker Deadpan (B) and contain actively dividing cells (PH3; C).\
(D) Expression of Lola-N in *lola*^*E76*^ mutant clones is sufficient to rescue the tumor phenotype.\
(E) actin FLP-out clones that express *lola shRNAi* (induced during the second instar larval stage) result in tumors in the adult brain (five out of nine brains). Arrowheads highlight dividing cells (PH3).\
(F) FLP-out clones that express both *lola shRNAi* and Prospero do not cause tumors (11 out of 11 brains). Clones are marked with GFP.\
Scale bars represent 100 μM. See also [Figure S3](#app3){ref-type="sec"}.](gr4){#fig4}

![In *lola* Mutants, Neuroblast Genes Are Switched Off in GMCs but Reexpressed in Neurons\
(A) In wild-type embryos Deadpan is switched off in GMCs and remains off.\
(B) In lolaE76 embryos Deadpan is switched off normally in GMCs; however, ectopic Deadpan is observed in the dorsal more differentiated region of the VNC (see filled arrowheads). Less organized actin structures are observed in lolaE76 embryos, compared to wild-type (see empty arrowhead), due to disruption of axonal projections.\
(C) Expression of Deadpan and FasII in wild-type stage 15 embryos. Ventral view at the level of midline neuroblasts.\
(D) Deadpan and FasII expression in lola mutant embryos. Arrowheads show cells expressing both Deadpan and FasII.\
(E) Coexpression of Deadpan and FasII in lola mutant clones in the developing optic lobe. Arrowheads show cells expressing both Deadpan and FasII.\
(F) Coexpression of Deadpan and Cut in lola mutant clones in the developing optic lobe. Arrowheads show cells expressing both Deadpan and Cut.\
Scale bars represent 20 μM. See also [Figure S4](#app3){ref-type="sec"}.](gr5){#fig5}

![Time Course of Dedifferentiation in *lola* Tumors\
(A--C) Time course of dedifferentiation in *lola* tumors. In the outer medulla cortex of the developing optic lobe, ectopic Deadpan is not observed until ∼72 hr after clone induction (see arrowheads).\
(D) Ectopic expression of the neuroblast gene Asense (see arrowheads).\
(E) Ectopic division (PH3) is observed ∼96 hr after clone induction (see arrowheads).\
Scale bars represent 20 μM. See also [Figure S5](#app3){ref-type="sec"}.](gr6){#fig6}

![*lola* Mutant Neurons Dedifferentiate to a Neural Stem Cell Fate\
(A and B) Knockdown of *lola* in the larval optic lobe medulla cortex causes neurons to dedifferentiate and express Deadpan (arrowheads in B). MARCM clones expressing *lola shRNAi* in a subset of neurons are labeled in green.\
(C) Schematic diagram showing the temporal expression of Deadpan, Prospero, and Lola-N during neuronal differentiation in embryos and the developing optic lobe.\
(D) Temporal expression of Deadpan, Prospero, and Lola-N during neuronal differentiation in the larval central brain.\
(E) In the *wild-type* nervous system Prospero turns off neural stem cell genes, such as Deadpan, in GMCs. In *prospero* mutants, neural stem cell genes continue to be expressed in GMCs, leading to overproliferation and tumors. In *lola* mutants, Prospero represses neural stem cell genes in the GMCs. However, in neurons, without Lola to maintain repression, neural stem cell genes are reexpressed, and the cells dedifferentiate and form tumors.\
See also [Figure S6](#app3){ref-type="sec"}.](gr7){#fig7}
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